B. Metzler seel. Sohn & Co. AG Buys New Shares in Bristol Myers Squibb Company $BMY

B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 101,975 shares of the biopharmaceutical company's stock, valued at approximately $5,876,000.

A number of other hedge funds also recently bought and sold shares of BMY. Norges Bank bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $1,947,272,000. AQR Capital Management LLC grew its position in shares of Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock worth $1,391,485,000 after buying an additional 16,332,924 shares during the period. BlackRock Inc. increased its stake in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock valued at $1,321,308,000 after acquiring an additional 7,837,485 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Up 2.4%

Bristol Myers Squibb stock opened at $67.06 on Friday. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The firm has a market cap of $136.98 billion, a P/E ratio of 14.77, a P/E/G ratio of 0.17 and a beta of 0.22. The business has a fifty day moving average of $60.55 and a two-hundred day moving average of $59.37. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.64.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the prior year, the firm earned $1.46 earnings per share. Bristol Myers Squibb's revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.8%. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.51%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on BMY. Piper Sandler began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set an "overweight" rating for the company. UBS Group lowered Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research report on Wednesday, August 5th. Jefferies Financial Group cut Bristol Myers Squibb from a "buy" rating to a "hold" rating in a research note on Wednesday, August 5th. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 27th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $66.06.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb plans to invest approximately $2.3 billion in a new Houston manufacturing facility, part of a broader $40 billion U.S. investment commitment. The project reinforces BMY’s confidence in domestic production capacity and could support long-term operational growth. Bristol-Myers Squibb Bets $2.3 Billion on Texas
• Positive Sentiment: BMY is collaborating with Chai Discovery on artificial-intelligence-driven antibody discovery. The partnership could help identify novel therapeutic candidates more efficiently and strengthens the company’s efforts to modernize its drug-development platform. Chai Discovery Collaboration
• Positive Sentiment: The company is launching a Phase 1 study of an early Alzheimer’s disease antibody. Although the program remains highly experimental, it adds another potential long-term growth opportunity to BMY’s pipeline. Early Alzheimer’s Antibody Study
• Positive Sentiment: Strong Eliquis performance is helping offset declines in BMY’s older products facing generic pressure, supporting a more favorable 2026 revenue outlook. Elevated call-option activity also signals increased bullish interest, though it is not a fundamental guarantee. Eliquis and Legacy Portfolio Analysis
• Neutral Sentiment: Early clinical work on navlimetostat shows continued pipeline activity, but the Phase 1-stage program has not yet produced efficacy data that would materially change near-term earnings expectations. Navlimetostat Study Update
• Negative Sentiment: Generic competition remains a key risk for BMY’s legacy portfolio. Investors must determine whether Eliquis growth and newer pipeline assets can replace revenue lost as established medicines face erosion. Legacy Portfolio Erosion Analysis

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source